A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer

A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer

Abstract Background Ovarian cancer has no definitive second line therapeutic options, and largely recurs in the peritoneal cavity. Locoregional immune therapy using both interferons and monocytes can be used as a novel approach. Interferons have both cytostatic and cytotoxic properties, while monocy...

Full description

Bibliographic Details
Main Authors: Daniel S. Green, Ana T. Nunes, Virginia David-Ocampo, Irene B. Ekwede, Nicole D. Houston, Steven L. Highfill, Hanh Khuu, David F. Stroncek, Seth M. Steinberg, Kathryn C. Zoon, Christina M. Annunziata
Format: Article
Language:English
Published: BMC 2018-07-01
Series:Journal of Translational Medicine
Subjects:
Cellular therapy
Immunotherapy
Monocytes
Interferons
Ovarian cancer
Intraperitoneal
Online Access:http://link.springer.com/article/10.1186/s12967-018-1569-5

Internet

http://link.springer.com/article/10.1186/s12967-018-1569-5

Similar Items